Active surveillance for prostate cancer — the systematic monitoring approach for low-risk and very-low-risk prostate cancer deferring treatment unless disease progression evidence emerges — represents the most significant shift in prostate cancer management philosophy, with the Prostate Cancer Market reflecting active surveillance as both a clinical advancement and a market dynamic.

Active surveillance adoption growth — the dramatic increase from approximately ten percent to over fifty percent of low-risk prostate cancer patients choosing active surveillance over immediate treatment at leading US institutions — reflects the evidence-based shift in management philosophy. The major active surveillance programs (PRIAS, UCSF UCSF AS, Johns Hopkins AS, University of Toronto) demonstrating excellent long-term outcomes (fifteen-year prostate cancer-specific survival exceeding ninety-five percent) supporting AS as appropriate management for properly selected low-risk patients.

Monitoring technology market for active surveillance — the PSA testing, repeat biopsy, MRI surveillance, and biomarker tests (Oncotype DX Genomic Prostate Score, Decipher, Prolaris) guiding AS decisions — create the diagnostic commercial market. The molecular genomic tests (Decipher, Oncotype DX Genomic Prostate Score, Prolaris) providing additional risk stratification to guide AS versus treatment decisions creating the precision diagnostics market.

Active surveillance exit triggers — the clinical, pathological, and molecular criteria prompting treatment including PSA kinetics, upgrading to Gleason grade group 2+, increased MRI lesion burden, or adverse genomic profile — define the monitoring boundaries within which patients remain on AS. The commercial interest in both extending AS duration (diagnostic tool companies) and optimizing AS exit timing (treatment companies) creating the commercial tension.

Do you think active surveillance will eventually apply to a broader population including some Gleason grade group 2 (Gleason 3+4=7) patients, substantially increasing the AS market while reducing early treatment?

FAQ

What is active surveillance and which patients are eligible? Active surveillance (AS): systematic monitoring with planned intervention only upon defined progression criteria; eligibility (per NCCN very low risk/low risk): PSA ≤10 ng/mL; Gleason grade group 1 (3+3=7); clinical stage T1c-T2a; PSA density <0.15 ng/mL/cc; few positive biopsy cores; monitoring protocol: PSA every three to six months; MRI-guided repeat biopsy at one to two years then every two to four years; mpMRI every one to three years; Gleason grade group 2 (3+4=7): favorable intermediate risk — AS appropriate at some centers per evolving NCCN guidance; approximately fifty percent of eligible patients choosing AS at major academic centers.

What biomarkers help guide active surveillance decisions? Genomic AS decision tools: Oncotype DX Genomic Prostate Score (GPS): Genomic Health/Exact Sciences; twenty-gene expression panel from biopsy cores; predicts metastatic risk and cancer-specific mortality; guides AS vs treatment decision; Decipher Prostate (GenomeDx/Veracyte): twenty-two gene genomic classifier; predicts metastatic disease; validated for post-prostatectomy staging and AS decision support; Prolaris (Myriad Genetics): forty-six gene cell cycle progression score; predicts disease specific survival; all commercially available, Medicare reimbursed; used with pathological grade and mpMRI to refine risk assessment.

#ProstateCancer #ActiveSurveillance #ProstateSurveillance #OnotypeDX #DecipherProstate #LowRiskProstate